Customflex Artificialiris - Custom-Color Match Medical Device

The safety and efficacy of the CUSTOMFLEX® ARTIFICIALIRIS was demonstrated in a non-randomized clinical trial of 447 eyes of 389 adult and pediatric patients with aniridia or other iris defects.

• There was a decrease in the severity of day-time symptoms of light sensitivity, glare and halos.
• There was a decrease in the severity of night-time symptoms of light sensitivity, glare, halos and starbursts.
• Reading was improved.
• Difficulty driving at night was improved.
• There was a three-fold improvement in patients' ability to complete normal vision-related activities of daily living, as measured by a standardized health related quality of life questionnaire.
• Satisfaction with the cosmetic appearance was high, with 93.8% of patients rating their appearance as “improved” to “very much improved” after implantation of the CUSTOMFLEX® ARTIFICIALIRIS.
• Although the CUSTOMFLEX® ARTIFICIALIRIS is not designed to improve vision, 67.2% of the eyes had better uncorrected visual acuity (vision without glasses or contact lenses) after the artificial iris surgery; and, 27.7% of the eyes had uncorrected vision that was unchanged.

• None of the eyes had a clinically significant loss of more than 2 lines on the eye chart of best corrected vision at 12 months postoperatively that was caused by the CUSTOMFLEX® ARTIFICIALIRIS.
• Increases in intraocular pressure greater than 30 mm Hg were the most common adverse event reported in the study.
• The CUSTOMFLEX® ARTIFICIALIRIS implant remained in its intended position in the majority of eyes throughout the 12 month study; secondary surgeries could be performed when needed to reposition the device.
• Inflammation occurring at one month or later after surgery was related to the CUSTOMFLEX® ARTIFICIALIRIS device in 0.7% of the eyes.

Contraindications: CUSTOMFLEX® ARTIFICIALIRIS is contraindicated for patients with certain eye conditions, such as uncontrolled inflammation, severe chronic uveitis, microphthalmus, untreated retinal detachment, untreated chronic glaucoma, rubella cataract, rubeosis of the iris, proliferative diabetic retinopathy, Stargardt’s retinopathy, or intraocular infections, or in pregnant women.

Warnings: Implantation of the CUSTOMFLEX® ARTIFICIALIRIS is not recommended in children who are less than 3 years of age because their eyes are still in a stage of major growth development that would be disrupted by ocular surgery. Refer to the Patient Information Brochure for complete study results, other warnings, precautions, and instructions for the use of the device.